Evoke Pharma, Inc.
NASDAQ: EVOK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mark A. Kowieski
- Employees
- 3
- Headquarters
- Solana Beach, United States
- IPO year
- 2013
- Market cap
- $18.9M
- Website
- https://www.evokepharma.com
Loading EVOK…
Loading profile data…Frequently asked questions about EVOK
What does Evoke Pharma, Inc. (EVOK) do?
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicin...
Where does EVOK trade?
Evoke Pharma, Inc. (EVOK) trades on the NASDAQ Capital Market.
What sector is EVOK in?
Evoke Pharma, Inc. (EVOK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Evoke Pharma, Inc.?
Mark A. Kowieski is the chief executive officer of Evoke Pharma, Inc. (EVOK).
Where is Evoke Pharma, Inc. headquartered?
Evoke Pharma, Inc. is headquartered in United States.
Does EVOK pay a dividend?
Evoke Pharma, Inc. (EVOK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EVOK go public?
Evoke Pharma, Inc. (EVOK) completed its initial public offering in 2013.